Skip to Content
Morningstar

Icon PLC ICLR

Morningstar Rating
Unlock
Stock XNAS Rating as of
$308.31 +8.23 (2.74%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

ICON Earnings: Strong Demand for Outsourced Clinical Trials; Focus on Innovative Data Solutions

Rachel Elfman

Narrow-moat Icon reported strong first-quarter results highlighted by revenue exceeding $2 billion, representing a nearly 6% increase from the prior-year period, thanks to stabilizing demand within the biotech customer base. We continue to have a positive outlook for Icon, and we maintain our fair value estimate of $268 per share. However, we view the stock as currently trading at a 12% premium to our fair value estimate.

Read Full Report

Price vs Fair Value

View History
ICLR is trading at a 14% premium.
Price
$306.45
Fair Value
$967.00
Uncertainty
Medium
1-Star Price
$823.90
5-Star Price
$849.80
Economic Moat
Cwztkc
Capital Allocation
Rtkvthf

Bulls Say, Bears Say

Bulls

Icon is highly exposed to the late-stage CRO industry, which due to its complexity is conducive to long-term competitive advantages.

Bears

Drawbacks to biotech funding or declines in outsourcing penetration rates could have a material impact on Icon's growth.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ICLR is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$300.08
Day Range
$300.25–310.41
52-Week Range
$181.92–344.77
Bid/Ask
$263.00 / $349.00
Market Cap
$25.49 Bil
Volume/Avg
715,419 / 558,598

Key Statistics

Price/Earnings (Normalized)
25.00
Price/Sales
3.10
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
41,150
Website
https://www.iconplc.com

Competitors

Valuation

View More
Metric
ICLR
MEDP
FTRE
Price/Earnings (Normalized)
 25.0041.5065.37
Price/Book Value
 2.7018.781.86
Price/Sales
 3.106.601.04
Price/Cash Flow
 19.1436.4926.55
Price/Earnings
ICLR
MEDP
FTRE

Financial Strength

Metric
ICLR
MEDP
FTRE
Quick Ratio
 1.160.591.52
Current Ratio
 1.210.641.62
Interest Coverage
 3.37688.871.02
Quick Ratio
ICLR
MEDP
FTRE

Profitability

Metric
ICLR
MEDP
FTRE
Return on Assets (Normalized)
 4.85%21.26%1.15%
Return on Equity (Normalized)
 9.19%67.47%2.40%
Return on Invested Capital (Normalized)
 8.41%49.10%3.06%
Return on Assets
ICLR
MEDP
FTRE
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Diagnostics & Research Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncShtjtglryLsf$209.3 Bil
DHR
Danaher CorpZwphswghJgdhlj$182.1 Bil
IQV
IQVIA Holdings IncHlkbwqbhDfwqlzq$42.8 Bil
IDXX
IDEXX Laboratories IncCpcfxwcfwRdfjgd$41.5 Bil
A
Agilent Technologies IncKcmxlnbfJpb$40.4 Bil
MTD
Mettler-Toledo International IncXqmbzlzhbqBhjhk$26.5 Bil
ILMN
Illumina IncCmzfgddxdWtsrgr$19.5 Bil
WAT
Waters CorpWbvccqczxKgj$18.5 Bil
LH
Laboratory Corp of America HoldingsVrhxmdsqwqKzvhyg$16.7 Bil

Sponsor Center